Single-dose Russian vaccine 70% effective against Delta variant
A single-dose Covid-19 vaccine developed in Russia has been shown to be 70% effective against the Delta variant. According to a Reuters report, Sputnik Light showed 70% effectiveness against the highly-contagious strain, 3 months after administration. The data was submitted by the Gamaleya Institute, developers of the vaccine, ahead of a peer review. The study was based on 28,000 trial participants who were given a dose of Sputnik Light, versus a control group of 5.6 million people who did not receive a Covid-19 vaccine.
Reuters reports that Russia is currently battling a surge in Covid-19 infections, coupled with vaccine hesitancy, while trying to compete with effective foreign vaccines such as Pfizer, AstraZeneca, and Moderna, whose manufacturers are producing hundreds of millions of doses. The Russian Direct Investment Fund says that if administered as a booster, the Sputnik Light vaccine would be nearly as effective as Russia’s 2-dose vaccine, Sputnik V. According to Kirill Dmitriev from the RDIF, which markets Sputnik V overseas, Sputnik Light would be 83% effective at preventing transmission and over 94% effective at preventing hospitalisation. He expects the single-dose vaccine to become Russia’s primary Covid-19 vaccine.
“Eventually, we believe that Sputnik Light could be the main vaccine one year from now when many people will just need to get re-vaccinated or will have had Covid and won’t need Sputnik V.”
For more information on Covid-19 Insurance, CLICK HERE.
SOURCE: Reuters
